Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Of course we need cash but then contradicting yourself saying NPX002 has very good results is why your diatribes of doom and gloom lack integrity.
NFT on his usual doom laden soapbox again … a good job we have great NXP 002 results and are actively seeking a partnership deal.
Moans when no communication, moans with communication.
Let us see … no harm in hoping as I don’t not much left to lose on his one :-(
In fairness Earl was correct about the RNS landing when it did despite naysayers denouncing his remarks … it would be great to see a partnership deal sooner rather than later that is for sure.
Funding would be a deal like RedX … end of
Before RedX acquired its deal in 2020 the share price bottomed out at 3.5p.
NFX has all to play for https://www.redxpharma.com/wp-content/uploads/2018/12/Redx-signs-out-licensing-agreement-with-AstraZeneca.pdf
Https://twitter.com/colinbirdmining/status/1659574921910013952?s=46&t=tUQTeRa0gKopv5Y7MfSmIA
We now have proof of action against cytokines, disease progression and a potential for a therapeutic window of at least 12 hours. Things are vastly different than in 2019.
The potential for NXP002 at this stage of the trials looks excellent. The main issue is the balance sheet and the pressure that places upon NFX to secure a partnership.
After all that NXP002 is ticking all the boxes …
Your comment is just a deflection due to your own bias ... you are not interested in results which is what is important. When you have something of interest to post based on the results and the next steps I will read it with interest. Till then you have nothing worth my time to read.
Read into it what you like FFxS ... the results are excellent and if you had IPF you would be very excited at the prospect of an improved therapy.
ChapGPT resume
- Demonstrated drug effectiveness in increasing response against inflammation and biomarkers through inhalation and dose escalation.
- Conducted research using high challenge disease models close to patient conditions, specifically focusing on patients with idiopathic pulmonary fibrosis (IPF) who are awaiting lung transplants.
- Obtained access to IPF patient lungs for testing the drug's impact on the fibrotic process.
- Utilized human IPF tissue as a test ground to gather valuable data and insights.
- Highlighted the importance of drug duration and its pharmacological effects after inhalation.
- Addressed the potential concern of the drug not staying in the system long enough for effective treatment.
- Significantly mitigated the preclinical development risk through the data obtained, instilling confidence in potential partners.
- Demonstrated the successful development potential of the drug and program for treating relevant disease progression.
Not hyping or denouncing but the trial revealed a 12-hour therapeutic window. As DC mentioned, if you are having to use an inhaler every hour and the current medications have more side effects then NXP002 has ticked a lot of boxes.
Everyone can keep backbiting if they want but todays RNS was gold standard.
The price is on the floor … it can only go up if deals are
made.
Agreed … GLR started from a very low base after
Concordia but CB has worked hard in developing a new portfolio mostly focused upon metals required for electrification. Very astute.
I’m in profit Kwodoku … all looking good to me !
Can’t read Pan’s diatribe as I have blocked them but I can tell the usual diatribe is underway.
Good news today as no one spends cash on someone else’s asset unless they perceive future value they can profit from.
Who gives away free cash on business ?
In response to VB